We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia
Monthly Production Capacity: 500kg
Contract Manufacturing: CMO
Packaging Information: 1kg, 2kg, 5kg/Bag
Delivery Lead Time: Prompt from stock
Sample Provided: yes
Payment Terms: T/T
1.Basic information:
Product name: Indole-3-carbinol
Appreance: White fine powder
Chemical name: Indolemethanol; Indole-3-carbinol; 3-(Hydroxymethyl)indole; 3-Indolemethanol; 1H-Indol-3-ylmethanol; Indole-3-methanol; 1H-Indole-3-methanol
CAS No.:700-06-1
EINECS No.:211-836-2
Molecular formula :C9H9NO
Molecular weight:147.18
Purity: ≥ 99% by HPLC
Melting Point(mp):96-99°C
Loss on drying≤0.5%
Use : Nutraceuticals, or intermediate for medicines
Package : 25kg per paper barrel
Storage : Refrigerate (+4°C). Protect from light
2.Indole 3 methanol 3-Hydroxymethylindole
Content
Specification
Results
Assay(HPLC)
≥99.0%
99.4%
Melting range
96.0-100.0
97.2-98.7
Residue on ignition
0.1%
0.04%
PH
5-8
6-7
Loss on drying
1.0%
0.46%
Pb
5ppm
Conforms
Arsenic
1ppm
Conforms
Total plate count
500cuf/g
Conforms
Moulds
100cuf/g
Conforms
E .coli
Negative
Negative
Salmonella
Negative
Negative
3. Description
Indole 3 Carbinol is a type of Indole. Chemically, it is a metabolite of Glucobrassicin, which in turn is a hydrolytic product of Glucosinolates.
Eight years of qualification
Audited Supplier
Pharma Sources Insight JANUARY 2024
